Erasing Cancer

Cancer Risk in Women after Bariatric Surgery

Erasing CancerThe long-term risk of cancer was reduced in women with severe obesity who got bariatric surgery compared to carefully matched patients who did not get bariatric surgery, according to new research published in the Annals of Surgery.

Obesity is a strong risk factor for many types of cancer. This study examined whether or not bariatric surgery affected the risk of developing cancer.

The results showed that bariatric surgery reduced the risk of cancer in women, particularly in obesity-associated cancers, including postmenopausal breast cancer, endometrial cancer, colon cancer, and pancreatic cancer.


Read More

Bariatric Radiology

Radiologists Develop Non-Surgical Weight Loss Treatment

Bariatric RadiologyA new non-surgical weight loss treatment, known as bariatric arterial embolization (BAE), could offer individuals a safe and effective alternative to weight loss surgery.

Researchers presented findings of the pilot clinical trial, Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity), at the 2016 Annual Scientific Meeting of the Society of Interventional Radiology.

According to study results, the treatment proved safe, with no major adverse events, and led to sustained weight loss and a dramatic reduction in hunger levels.


Read More

Weight Loss Satisfaction

Long-Term Safety and Weight Loss After BPD and Duodenal Switch

Weight Loss SatisfactionNew research supports the long-term safety and efficacy of biliopancreatic diversion (BPD) with or without duodenal switch (BPD/DS).

These two weight loss surgery variations are highly complex and drastic procedures that involve bypassing a large portion of the small intestine to limit food absorption. They are generally appropriate options only for patients with a very high body mass index (BMI of 50 or greater).

The study found that overall patients experienced high levels of excess weight loss and while nutritional deficiencies and postoperative complications were high, patients were satisfied with their choice of surgery.


Read More

Apollo Overstitch

Endoscopic Sleeve Gastroplasty – A New Weight Loss Option

A new treatment method known as endoscopic sleeve gastroplasty is showing promise as a minimally invasive, safe and cost-effective weight loss intervention for patients with obesity.

Researchers at the Mayo Clinic in Rochester, Minnesota have been investigating this weight loss option and have recently published the results of a second study.

The first study demonstrated the technical feasibility and safety of the procedure; this second study investigated durability, weight loss, and gastrointestinal function.


Read More

VBLOC Therapy by EnteroMedics

ASMBS Issues Position Statement on VBLOC for Obesity

VBLOC Therapy by EnteroMedics The American Society For Metabolic And Bariatric Surgery (ASMBS) recently issued a Position Statement on Vagal Blocking Therapy for Obesity.

VBLOC, or Vagal Blocking Therapy, is a new therapy for weight loss that uses an implantable, pacemaker-like device to intermittently disrupt the vagus nerve signaling between the brain and the stomach, affecting perceptions of hunger and fullness.

The VBLOC device, the Maestro Rechargeable System, was developed by EnteroMedics of St. Paul, Minnesota. It was approved by the U.S. Food and Drug Administration (FDA) in January 2015.


Read More

Lap Band System

LAP-BAND Works in Lower BMI Patients

LAP-BAND SystemA 5-year study on the use of the LAP-BAND System in lower BMI (body mass index) patients reported positive health and weight loss outcomes.

Weight loss surgery has traditionally been limited to patients with a BMI of at least 40, or at least 35 with a severe related health condition such as type 2 diabetes or heart disease.

In 2011, the Food and Drug Administration (FDA) approved the request to lower the BMI requirements for the LAP-BAND to include patients with a BMI of 30 to 34 with an existing obesity related health condition.


Read More

ORBERA Weight Loss Balloon

FDA Approves ORBERA Balloon for Weight Loss

ORBERA Intragastric BalloonThe ORBERA Intragastric Balloon from Apollo Endosurgery, Inc. was approved by the FDA on August 6, 2015 as a non-surgical weight loss treatment for adults with obesity.

The ORBERA balloon is designed to occupy space in the stomach and assist with weight loss by reinforcing portion control. The balloon remains in place for six months and is part of a 12-month supervised diet and exercise program, known as the ORBERA Managed Weight Loss System.

The approval comes only a week after the FDA approved another gastric balloon weight device, the ReShape Integrated Dual Balloon System from ReShape Medical.


Read More


ReShape Medical Weight Loss Device Gets FDA Approval

FDA Approved A new non-surgical and non-permanent option for weight loss is now approved to treat obesity in the United States, the ReShape Integrated Dual Balloon System.

The U.S. Food and Drug Administration approved the ReShape System on July 28, 2015 after a review of study results and finding the medical device proved safe and effective in clinical trials.

The ReShape weight loss procedure is a gastric balloon system that offers patients proven weight loss without surgery, dual balloon technology for increased satiety, comfort, and safety, and one year of diet and exercise counseling to maximize satisfaction and success.


Read More


Gender Affects Bone Health After Bariatric Surgery

OsteoporosisBariatric surgery increases the risk of osteoporosis and fractures in women, according to results from the Swedish Obesity Subjects (SOS) study. The elevated risk was not observed in men.

The researchers stated that while several other studies have shown that bone-mineral density declines within 9 to 12 months after bariatric surgery, very few studies have investigated whether this leads to a long-term risk of osteoporosis.


Read More

Gastric Bypass Outcomes

Gastric Bypass Long-Term Outcomes

Weight Loss WomenAn investigation into the long-term outcomes of the Roux-en-Y gastric bypass (RYGB) presents updated information on how weight loss, health improvements, and nutritional status holds out over time.

Immediate results of RYGB are well-studied and continue to show that patients are able to lose a significant amount of weight quite quickly. Nearly half of all weight loss occurs during the first six months after surgery and peaks at 18 to 24 months. Health improvements are noted as well.

While numerous short and mid-term studies have been completed, few long-term studies are available, especially with information on current techniques and laparoscopic procedures.


Read More